China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Merck’s $2.13B deal with SciBrunch for KRAS G12D inhibitor SPR2015, Abogen’s $7.78B partnership with Novartis for an mRNA T-cell engager, and 3SBio’s ¥1.75B GLP-1 deal with MindRank. Other updates feature AstraZeneca’s $2B investment in Summit, Hengrui’s $2.6B GLP-1/GIP deal…
USA Falling prices are squeezing US generic and biosimilar manufacturers too hard, argues John Murphy III, President and CEO of the Association for Accessible Medicines (AAM). Generic prices have dropped an average of 7.7 percent a year over the past five years while medical inflation ran at 6.2 percent, and Murphy…
India Ajay Mahipal of India-focused healthcare impact and venture capital investment platform HealthKois argues that India’s life-sciences ecosystem is approaching an inflection point. Having built its reputation on manufacturing scale, the country now has a narrow window to build the clinical-development capabilities needed to originate and test novel therapies itself. India…
China Chinese biotechs are now outpacing multinationals at getting drugs into pivotal trials — but MNCs still win the race to final approval. In this piece from the September 2026 edition of DIA Global Forum, Li Wang of Lilly’s China Drug Development & Medical Affairs Center digs into fresh 2023–2025 timeline…
Singapore Singapore’s Health Sciences Authority has become one of the world’s most respected drug regulators, earning WHO maturity level 4 status and a seat at tables like the Access Consortium and Project Orbis. Writing in the September 2026 edition of DIA Global Forum, Sandy Chan, Sok Bee Lim, Shirley Yong, and…
China Chinese pharmaceutical companies are increasingly seeking drug approval in the EU, US, and Australia, beyond the NMPA. Daphne Smyth of Veristat has witnessed this shift firsthand, advising sponsors on data gaps, supplementary studies, and the regulatory quirks that stand in the way of a drug developed in China gaining marketing…
Global Five conferences, anxiety spreading across five continents, one unmistakable pattern: the global pharmaceutical industry is transforming at a dizzying pace. From Philadelphia to Geneva, from Istanbul to Chicago and London, the Shawview Consulting team picked up the same recurring threads in every panel and hallway conversation: AI and real-world data…
Global In debates over drug pricing, affordability and innovation are often framed as a zero-sum trade-off. Zeba M. Khan, Editor-in-Chief of ISPOR’s Value & Outcomes Spotlight, argues it doesn’t have to be, provided pricing policy is grounded in evidence rather than blunt measures. Khan examines the IRA’s Medicare reforms, the fallout…
Africa Can a medicine be considered “available” if it can’t be trusted? As Africa’s manufacturing base expands and its regulatory systems mature, that question is moving to the centre of the continent’s health agenda. Lenias Hwenda maps out why 2026 is a turning point for African patient safety — anchored by…
USA A sustainable market for generics and biosimilars is the key to lowering the cost of medicine in the US, says John Murphy III, President and CEO of the Association for Accessible Medicines. Following leadership changes within the FDA, actively prioritizing generic and biosimilar medicines must remain a top focus…
Europe Strong patent portfolios can create substantial commercial value for biopharma companies. As Isobel Barry, partner at life sciences-focused IP firm Carpmaels & Ransford LLP explains, opportunities to patent new small molecule, biologics and complex therapeutics arise throughout the go-to-market process, from early-stage research, through formulation development and clinical trials, up…
Global Across the Global South, hundreds of millions of people live without reliable access to basic healthcare. Too few doctors, too little data, and systems too fragile to scale. However, as Capria Ventures’ Francis Perelman outlines, a new wave of AI-native startups is building for precisely those conditions, deploying tools that…
See our Cookie Privacy Policy Here
